TMCnet - World's Largest Communications and Technology Community



Research and Markets: Breast Cancer Drug Pathway Analyzer 2014
[May 08, 2014]

Research and Markets: Breast Cancer Drug Pathway Analyzer 2014

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Breast Cancer Drug Pathway Analyzer 2014" report to their offering.

There are today at least 532 targeted molecular therapies known to affect more than 253 specific intracellular signaling pathways for the treatment of breast cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 290 drug targets that are included in this drug-pathway analyzing tool. No less than 287 of these have been recorded with mutations and 49 drug targets have mutations which have been causally implicated in cancer.

Pathway Coverage

  • BioCarta # 253 Pathways
  • KEGG # 197 Pathways
  • NCI-Nature # 252 Pathways
  • NetPath # 32 Pathways

Pipeline Coverage

  • Marketed # 55
  • Pre-registration # 1
  • Phase III # 31
  • Phase II # 188
  • Phase I # 113
  • Preclinical # 138
  • No Data # 1
  • Suspended # 8
  • Ceased # 207

The continuous identification of drug targets and pathways that are altered in cancer is not only crucial for our understanding of cancer biology, but also to search for new targets for early diagnosis and improved treatment designs. Consequently, it has never before been as important to rapidly translate systems biology of disease and therapeutics to actionable pipeline decisions to ensure that the optimal market conditions exist by the time a candidate drug is commercialized.

You Use this Analyzer Tool in Breast Cancer to:

  • Map the competition and find suitable benchmarking/licensing drugs based on specific pathways and drug properties
  • Uncover potential indication expansion areas for your drug portfolio
  • Reveal repositioning opportunities for your older, shelved drugs
  • Evaluate the progression and success of targeting certain pathways by different tumor types
  • Investigate drugs which affect crosstalk between key pathways
  • Investigate different combination therapy options available to you in various cancer types. Use this tool to look for the most-efficient ways to combine your drug with other targeted agents.
  • Find possible adjuvant therapy settings with other drugs.

For more information visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy